NBCF is joining forces with some of the greatest scientists and doctors in the world to eliminate barriers in the fight against breast cancer through a collaborative event.
While NBCF provides mammograms for underserved women across the United States, they recognize their ground-breaking educational initiatives are needed throughout the world to illuminate people’s awareness of breast cancer.
The WIN Consortium is a joint initiative of the Institut Gustave Roussy and the University of Texas M. D. Anderson Cancer Center, in association with other leading cancer care institutions around the World. The Consortium aims to build new strategic alliances in oncology, creating innovative drug development programs and accelerating clinical trials and validation of new drugs for personalized cancer care.
This major event, entitled Worldwide Innovative Networking in Personalized Cancer Medicine 2010 (WIN 2010), will present breakthrough scientific technologies and achievements in personalized cancer medicine, with a special focus on individualized treatment and early diagnosis of cancer. The Symposium, to be held in the Palais de Congres, Paris, on July 7-9th 2010, will offer an interactive forum to discuss new approaches, tools, and challenges in cancer medicine. Registered attendees are invited to submit questions at www.mfcongress.com.
In partnership with research doctors from The University of Texas M. D. Anderson Cancer Center, NBCF executives met with Professor Thomas Tursz, General Director at the Institut Gustave Roussy, and Dr. Vladimir Lazar, Co-coordinator of the WIN Consortium and Head of Functional Genomics at the Institut Gustave Roussy, in Paris, France to coordinate their sponsorship efforts in support of the upcoming WIN Consortium.
“As breast cancer cases and mortality rates continue to rise across the globe, it is becoming increasingly urgent for the medical community to share their successes and failures in the fight against this disease,” says Janelle Hail, NBCF Founder & CEO.
“The WIN Consortium is made up of clinicians, researchers, and technology providers dedicated to ensuring rapid translation of ground-breaking personalized cancer medicine discoveries from the bench to the bedside,” said Dr. Lazar.
According to Hail, this type of consortium and unselfish collaboration with the finest doctors and scientists in the world could significantly accelerate the goal to save lives.
About WIN Consortium
The WIN Consortium is a joint initiative at the Institute Gustave Roussy and the University of Texas M. D. Anderson Cancer Center, in association with several other leading cancer care institutions in Europe, the United States of America, Canada and Asia. “The WIN Consortium’s aim is the rapid translation of ground-breaking personalized cancer medicine discoveries from the bench to the bedside”. Its SITED program (Standards in Individualized Treatment and Early Diagnosis) brings together academia and industry, undertaking a range of research and clinical projects to improve early diagnosis of cancer and to establish new treatment strategies.
About the National Breast Cancer Foundation, Inc.
Recognized as one of the leading breast cancer organizations in the world, NBCF’s mission is to save lives through early detection and to provide mammograms for those in need. NBCF provides Help for Today…Hope For Tomorrow® through its National Mammography Program, Early Detection Plan®, MyNBCF online social community, and innovative breast cancer educational and research programs. For more information about NBCF, visit www.nbcf.org.